secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-268807
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Q3 2023 VOWST sales $7.6M; cuts 41% workforce, targets $75-85M annual savings
--------------------------------------------------------------------------------

- Q3 net loss $47.9M vs $60.0M YoY; VOWST net sales $7.6M from 506 units in first full quarter.
- 1,513 prescription enrollment forms received, 934 patient starts; 698 unique HCPs prescribed VOWST.
- Workforce reduction of ~160 positions (41%) to generate $75-85M annual cash savings in 2024.
- Restructuring focuses on VOWST launch and SER-155 Phase 1b study; cash $169.9M expected into Q4 2024.
- Eligible for $45M Tranche B from Oaktree upon $35M trailing VOWST sales by Sep 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312523268807/0001193125-23-268807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312523268807/d559654d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer